# Epimède SA

> Epimède SA is a VC fund backing Biotechnology, Medical and Health Care. See 5 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Total investments: 5
- Last investment: Feb 2021
- Lead investor: 40%
- Last updated: Aug 2026

Epimède SA is a VC fund focused on Biotechnology and Medical. Epimède SA

## Contacts

5 contacts available for Epimède SA. Shizune tracks 1 team members at Epimède SA. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/epimède-sa?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series B | $12M–$26M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 60% |
| Medical | 2 | 40% |
| Health Care | 2 | 40% |
| Pharmaceutical | 2 | 40% |
| Life Science | 1 | 20% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 2 | 40% |
| Series C | 1 | 20% |
| Series D | 1 | 20% |
| Funding Round | 1 | 20% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Belgium | 3 | 60% |
| The Netherlands | 1 | 20% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Marc Foidart | Investment Manager | 2 | https://shizune.co/investors/profile/marc-foidart |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Imcyse | Imcyse is a clinical stage biopharmaceutical company pioneering the development of a new class of active specific immunotherapies for the treatment of severe chronic autoimmune diseases. The company’s unique technology platform allows it to locally target immune cells involved in the destruction of the diseased organ. This platform is based on theadministration of Imotopes™, which are specifically modified peptides, allowing for the generation of cytolytic CD4 T-cells, that specifically eliminate antigen-presenting cells and autoantigen specific lymphocytes. Imcyse’s approach, sustained over time, helps to prevent and treat diseases with no current therapeutic alternative and to potentially cure patients without impairing immune defense. The company has established proof of concept in several indications and has completed its first clinical trial in type 1 diabetes with promising results. Beyond type 1 diabetes, Imcyse is developing a pipeline of Imotopes™ for the treatment of several autoimmune diseases. | $25.7M | Series B | Feb 17, 2021 |  |
| Endo Tools Therapeutics | Endo Tools Therapeutics (ETT) is a privately held medical device company in Brussels Belgium, that was established in October 2008. The company is dedicated to the development of innovative devices providing new means of therapeutic interventions for gastroenterologists.ETT is currently developing a catheter that will add therapeutic channelsand degrees of freedom for interventional gastro-enterology. | $9.7M | Series D | Jan 19, 2021 |  |
| Endo Tools Therapeutics | Endo Tools Therapeutics (ETT) is a privately held medical device company in Brussels Belgium, that was established in October 2008. The company is dedicated to the development of innovative devices providing new means of therapeutic interventions for gastroenterologists.ETT is currently developing a catheter that will add therapeutic channelsand degrees of freedom for interventional gastro-enterology. | $5.5M | Series C | Feb 11, 2019 |  |
| Ncardia | Ncardia is an Operator of a biotechnology company intended to expedite drug discovery and development process.The company uses hiPSC stem cell technology to develop predictive human cellular assay systems for safety and efficacy testing of drug candidates as well as enhance cardiovascular and neural drug screening, enabling researchers to bringpredictive human disease biology and accelerate drug discovery. | $11.5M | Series B | Nov 17, 2017 |  |
| Diagenode | Diagenode is an international life sciences company that develops and commercializes innovative instruments and reagents systems for life science research and molecular diagnostics. Founded in 2003 in Liege (Belgium), Diagenode is a global company, with headquarters in Liege, Belgium and Sparta, NJ, USA. Diagenode also has a local sales office inthe United Kingdom to better serve this specific country.Diagenode's customers include leading epigenetics researchers, academic institutions, high-profile genome centers and core labs, life sciences tools companies, molecular diagnostics players, and pharmaceutical and biotechnology companies.Epigenetics Division | $8.2M |  | Jun 20, 2016 |  |

5 of 5 investments shown.

## Co-investors
- [SFPI-FPIM](https://shizune.co/investors/profile/sfpi-fpim) — VC Fund, 4 deals together
- [S.R.I.W.](https://shizune.co/investors/profile/s-r-i-w) — VC Fund, 3 deals together
- [Chagral Invest](https://shizune.co/investors/profile/chagral-invest) — VC Fund, 2 deals together
- [Biogenosis](https://shizune.co/investors/profile/biogenosis) — VC Fund, 1 deal together
- [Capricorn Partners](https://shizune.co/investors/profile/capricorn-partners) — VC Fund, 1 deal together
- [InnovationQuarter](https://shizune.co/investors/profile/innovation-quarter) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [PMV](https://shizune.co/investors/profile/pmv-eu) — VC Fund
- [Limburgse Reconversie Maatschappij](https://shizune.co/investors/profile/limburgse-reconversie-maatschappij) — VC Fund
- [Qbic Fund](https://shizune.co/investors/profile/qbic-fund) — VC Fund

## Featured in investor lists
- [Life Science Investors in Belgium](https://shizune.co/investors/life-science-investors-belgium)
- [Life Science VC Funds in Belgium](https://shizune.co/investors/life-science-vc-funds-belgium)

## FAQ

### What does Epimède SA invest in?

Epimède SA invests primarily in Biotechnology, Medical and Health Care startups, most often at Series B and Series C stage. Most of the 5 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Epimède SA's check size?

Epimède SA typically joins rounds of $12M–$26M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Epimède SA participates in.

### How do I contact Epimède SA?

For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Epimède SA?

The team at Epimède SA includes Marc Foidart (Investment Manager). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co